Amylyx Pharmaceuticals Inc (AMLX)

Holding for the big money. Had a nice week on my Rolls Royces selling 100 share blocks - next one is set to go at $21 I really think $25 - $30 is where it will wind up. Then I sold 5000 shares of SHAZW(all they gave me) total cost $9.45 including commish and sold for $1598.xx

Doubt next week will be as good but the guppy just keeps on swimming looking for new tickers.

Rolls Royce is my SMR - Small Modular Reactor ticker but found NKLR and looking to get a starter there.

I love this game

Fantastic. congrats

Kiwi

Not yet currently 660% showing but then again it's all profit since I sold enough for 200% wayyyyyy long ago. My cost basis is $2.406

Are U up about 10X on this ??

Kiwi

Karen Firestone from CNBC ..ex Fidelity biotech fund manager I think
Karen Firestone (Amylyx Board Member): She is the co-founder, CEO, and Chairman of Aureus Asset Management.
She sits on the Amylyx Board as a member of both the Audit and the Nominating and Corporate Governance committees.

Kiwi

Sounds like a winner to me.

To correct myself ....:---)
What Actually Drove Guggenheim's Model Increase?
Guggenheim raised its price target on Amylyx to $40 due to structural dynamics specific to the Post-Bariatric Hypoglycemia (PBH) market rather than public diabetic trends

:Solving a Critical Complication:
PBH is a severe, chronic complication affecting roughly 8% of bariatric (weight-loss) surgery patients. In these individuals, eating triggers a radically exaggerated, natural surge of GLP-1.
This causes the pancreas to pump out way too much insulin, dropping their blood sugar to dangerous, fainting-level lows. Avexitide blocks this overreaction.

The Monopoly Advantage:
There are currently no FDA-approved therapies for PBH. Because avexitide has shown strong Phase 2 data and is approaching its pivotal Phase 3 LUCIDITY trial readout, Guggenheim expects it to command a virtual monopoly (90% market share) because there are very few viable competitors in the pipeline

.Clinical Endorsement:
Recent physician feedback gathered by Wall Street analysts indicates that doctors are highly eager to prescribe a target blocker broadly to severe patients as soon as it passes regulatory hurdles.

The market penetration increase to 70% reflects Wall Street's confidence that physicians will aggressively adopt this specific "blocker" framework to treat severe medical accidents arising from weight-loss surgeries—not because more diabetics are taking standard GLP-1 injections

----------
AI assist
Kiwi

The expanded access program ...available to those who have completed the trial .

The FDA reviewed and authorized the implementation of this specific program.
Under U.S. federal regulations, any intermediate-size or large-scale Expanded Access Program (EAP) must receive regulatory review and authorization from the FDA before a pharmaceutical company can officially launch it or ship the investigational drug to patients.

However, it is crucial to understand the regulatory distinction:
EAP Authorization Received:
The FDA authorized the protocol allowing Amylyx to provide avexitide to an intermediate population of up to 250 eligible adults who have no other viable treatment options.
Not "FDA Approved" for the Public:
The drug itself, avexitide, remains an unapproved investigational treatment. It is not yet approved for general marketing or standard prescription use.
--------------
My take .
Theres enough completed data for the FDA to know it's at least safe ....and probably effective ( to what degree ...we await the P 3 results ) .
Would have killed the stock if the FDA had declined expanded access to..Sooooo ...looks good , may add

Kiwi
PS. Guggenheim may have upped their target partly on increased use of GLP-1's by the public . Some diabetics may experience severe hypoglycemia requiring AMLX's drug ...not sure ...just trying to understand it

Guggenheim’s updated model reflects increased GLP-1R antagonism penetration in severe PBH patients to 70% from 60% and higher long-term severe PBH GLP-1R antagonism market share for Amylyx at 90% from 70%.

Good to know because I was thinking about letting it go but now I have a reason to hold

Guggenheim raises Amylyx stock price target on PBH drug outlook
Analyst Ratings
Published 06/25/2026, 08:29 AM


Investing.com - Guggenheim raised its price target on Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) to $40 from $30 on Wednesday while maintaining a Buy rating on the shares.

The firm elevated Amylyx to its Best Idea designation from Top Pick ahead of the pivotal Phase 3 LUCIDITY trial readout expected in the third quarter of 2026 for avexitide in post-bariatric hypoglycemia.

The stock currently trades at $17 with a market capitalization of $1.89 billion, up 172% over the past year. While analyst targets range from $19 to $34, InvestingPro data suggests the stock may be overvalued at current levels.
Investors seeking deeper insights can access a comprehensive Pro Research Report on AMLX, one of 1,400+ US equities covered with actionable intelligence.

Guggenheim’s updated model reflects increased GLP-1R antagonism penetration in severe PBH patients to 70% from 60% and higher long-term severe PBH GLP-1R antagonism market share for Amylyx at 90% from 70%.
The firm removed non-PBH pipeline estimates for Wolframs from its projections.
The $40 price target represents a $5.3 billion market capitalization and approximately $2.5 billion in revenue in 2035, driven by penetration of approximately 30,000 most severe U.S. PBH patients. Guggenheim’s bull case of $55 assumes 10% penetration of the moderate segment within approximately 160,000 moderate-severe U.S. patients.
Avexitide would be the first FDA-approved treatment in what Guggenheim estimates is a $6 billion-plus U.S. PBH opportunity, based on either $100,000 per year for 160,000 moderate-severe patients or $200,000 per year for 30,000 of the most severe patients.

In other recent news, Amylyx Pharmaceuticals reported a first-quarter 2026 loss per share of $0.37, which did not meet analysts’ expectations of a $0.33 loss per share.
This earnings miss was accompanied by increased operating expenses.
Additionally, Amylyx presented early safety data for its ALS drug candidate, AMX0114, from the Phase 1 LUMINA trial, showing no drug-related serious adverse events in Cohort 1.
The company also published results from its Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, indicating continued improvements in pancreatic beta cell function through Week 48.
H.C. Wainwright reiterated its Buy rating and set a $34.00 price target for Amylyx, following insights from the PBH trial. These developments reflect Amylyx’s ongoing efforts in clinical trials and its financial performa

--------------
Kiwi

Guggenheim Securities upgraded Amylyx Pharmaceuticals (AMLX) to its "Best Idea" designation, raising the price target to $40 from $30 based on increased market penetration expectations for its avexitide treatment, which has an estimated $6 billion addressable market.
The firm projects further upside, including a $55 bull case target, ahead of the Phase 3 LUCIDITY trial results expected in Q3 2026. For more details, visit Investing.com.

Kiwi

Published yesterday:

ock is gaining attention as multiple pipeline programs move toward important clinical milestones in 2026.
The company’s Avexitide candidate targets post-bariatric hypoglycemia, offering a niche but potentially first-in-class GLP-1 antagonist opportunity.
Investors may see the largest long-term upside from Amylyx’s ALS program, though commercialization remains years away.
Five stocks to consider instead of Amylyx Pharmaceuticals.

The idiom “never judge a book by its cover” can cut both ways when it comes to clinical-stage biotechnology companies like Amylyx Pharmaceuticals NASDAQ: AMLX. The stock is up over 140% in the last 12 months as the company has made progress on its pipeline.

Amylyx Pharmaceuticals Today
Amylyx Pharmaceuticals, Inc. stock logo
AMLXAMLX 90-day performance
Amylyx Pharmaceuticals
$13.58 0.00 (0.00%)
As of 05/22/2026 04:00 PM Eastern
52-Week Range$4.64
?
$18.60
Price Target$23.00
One of the drugs in the pipeline is Avexitide, a treatment for post-bariatric hypoglycemia after Roux-en-Y gastric bypass surgery. In early May, Amylyx announced it had completed full enrollment in its Phase 3 trial, LUCIDITY. Topline results are expected in Q3 2026, which is pivotal for the short-term outlook for AMLX.

https://www.marketbeat.com/originals/amylyx-stock-why-the-full-pipeline-story-matters/?utm_source=www.tickertalk.com&utm_medium=newsletter&utm_campaign=as-small-cap-outperformance-continues-these-2-etfs-provide-exposure

Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical InvestigationMay 15, 2026 12:11 PM
Business Wire Peer-reviewed publication reports Week 24 and Week 48 results from Phase 2 HELIOS trial of AMX0035 in Wolfram syndrome, reinforcing consistency of observed stabilization or improvement across multiple outcomes related to disease progression, including pancreatic beta cell function, glycemic control, vision, and overall symptom burden AMX0035 was generally well-tolerated, consistent with previously presented safety data The Company continues to work with the FDA on a Phase 3 trial in Wolfram syndrome Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS clinical trial of AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol, in adults living with Wolfram syndrome have been published in The Journal of Clinical Investigation, a peer-reviewed medical journal. The publication reports Week 24 and Week 48 results from the Phase 2 open-label HELIOS trial previously presented in part at medical meetings. Consistent with earlier disclosures, the findings indicate continued improvements observed in pancreatic beta cell function through Week 48, as measured by C-peptide response to a mixed-meal tolerance test. Additionally, secondary measures of glycemic control, including HbA1c and time in target glucose range (70–180 mg/dL), demonstrated improvement from baseline at Weeks 24 and 48, while best-corrected visual acuity trended toward stabilization over the 48-week period. Participant and Clinician Global Impression of Change assessments also classified participants with available data as responders, defined by improvement or disease stabilization. “Wolfram syndrome is a rare genetic disease that presents significant challenges for patients and their families. It typically begins in childhood, with insulin-requiring diabetes and progressive optic nerve changes affecting vision, and over time can involve broader neurological symptoms that increasingly affect daily life, with no disease-modifying treatments approved today,” said Fumihiko Urano, MD, PhD, Principal Investigator of the HELIOS trial and the Samuel E. Schechter Professor of Medicine in the Division of Endocrinology, Metabolism & Lipid Research at Washington University School of Medicine in St. Louis. “In this context, the publication of the HELIOS results at Weeks 24 and 48 is highly encouraging. The observed objective improvement in pancreatic function and visual acuity stabilization over 48 weeks, combined with a favorable safety profile, reinforces AMX0035’s potential to meaningfully alter the trajectory of this disorder.” “We are excited to share the peer-reviewed publication of these results, which details the clinical findings of AMX0035 at Week 24 and 48 across both the endocrine and neurodegenerative manifestations of Wolfram syndrome. These findings are encouraging given that all trial participants were at least 17 years old, and their disease course had advanced considerably by the time of enrollment,” said Camille L. Bedrosian, MD, Chief Medical Officer at Amylyx. “We extend our deepest gratitude to Dr. Urano, the clinical trial site staff, and most importantly, the trial participants and their families. Your unwavering dedication makes this research possible as we continue to work with the FDA on a Phase 3 clinical trial in Wolfram syndrome.” The peer-reviewed publication also details qualitative interviews that reinforced the clinical relevance of these objective outcomes, with participants indicating meaningful improvements in diabetes and vision problems. Furthermore, the published safety findings remained consistent with prior clinical experience with AMX0035, with reported adverse events being mild or moderate and no serious adverse events related to treatment. HELIOS is a single-site, single-arm, open-label, Phase 2 clinical trial investigating AMX0035 in 12 adults living with Wolfram syndrome for up to 208 weeks followed by a four-week safety follow-up. The Company expects to present additional longer-term data from HELIOS at an upcoming scientific meeting. About AMX0035
AMX0035 is an oral, fixed-dose combination of sodium phenylbutyrate (PB) and taurursodiol (TURSO; also known as ursodoxicoltaurine outside of the U.S.). AMX0035 was designed to slow or mitigate neurodegeneration by targeting endoplasmic reticulum (ER) stress and mitochondrial dysfunction, two connected central pathways that lead to cell death and neurodegeneration. Amylyx believes that its proprietary combination of PB and TURSO and their complementary mechanisms of action will allow us to synergistically target abnormal cell death to better prevent neurodegeneration than treatment targeted at either mechanism of action alone. The FDA and the European Commission granted Orphan Drug Designation to AMX0035 for the treatment of Wolfram syndrome in November 2020 and August 2024, respectively. About Wolfram Syndrome
Wolfram syndrome is a rare, monogenic, progressive neurodegenerative disorder that progressively impacts multiple organs and systems. Wolfram syndrome is characterized by childhood-onset diabetes mellitus, optic nerve atrophy, and neurodegeneration. Common manifestations of Wolfram syndrome include diabetes mellitus and diabetes insipidus, gradual vision loss leading to blindness, hearing loss, neurogenic bladder, difficulties with balance and coordination, and difficulty breathing that can lead to respiratory failure and premature mortality. Wolfram syndrome is most commonly caused by pathogenic variants in Wolfram syndrome type 1 gene (WFS1). Because of the clear link between WFS1 mutations and endoplasmic reticulum (ER) stress, Wolfram syndrome is considered a prototypical ER stress disorder. Wolfram syndrome affects approximately 3,000 people living in the U.S., and there are currently no FDA-approved treatment options. About the HELIOS Trial
HELIOS (NCT05676034) is a 12-participant, single-site, single-arm, open-label, Phase 2 trial designed to evaluate the safety and tolerability of AMX0035, as well as its effects on various measures of endocrinological, neurological, and ophthalmologic function in adult participants living with Wolfram syndrome. Participants in HELIOS receive AMX0035 for up to 208 weeks followed by a four-week safety follow-up. Primary and secondary outcomes are assessed at Week 24 and at longer-term time points. About Amylyx Pharmaceuticals
At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com. Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx’s expectations regarding: the potential of AMX0035 (sodium phenylbutyrate and taurursodiol) as a treatment for Wolfram syndrome; and plans for a Phase 3 trial of AMX0035 in Wolfram syndrome. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx’s program development activities; Amylyx’s ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx’s ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx’s operations, as well as the risks and uncertainties set forth in Amylyx’s United States Securities and Exchange Commission (SEC) filings, including Amylyx’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. View source version on businesswire.com: https://www.businesswire.com/news/home/20260514300018/en/ Media
Amylyx Media Team
+1 (857) 320-6191
amylyxmediateam@amylyx.com Investors
Lindsey Allen
Amylyx Pharmaceuticals, Inc.
+1 (857) 320-6244
Investors@amylyx.com Original: Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation

LUCIDITY trial is estimated to be ≥90%
powered to detect a 35% relative
improvement over placebo even with up
to a 50% placebo effect

Just listened to presentation . They certainly dont want RZLT's problem with placebo effect .
Looks good
Kiwi

Key Points

Amylyx expects Phase 3 LUCIDITY data in Q3 after completing enrollment; the trial uses a 90 mg once-daily morning injection with a 16-week double-blind period and a composite primary endpoint of Level 2 and Level 3 hypoglycemic events.

The company is preparing for a potential commercial launch in 2027, says it has more than $300 million cash (running into 2028) to fund operations and holds patents on avexitide through 2037.

Avexitide is a GLP-1 receptor antagonist and prior Phase 2b data showed clinical activity (including a reported ~64% reduction in the composite endpoint and a median patient with zero events), supporting FDA Breakthrough Therapy designation in PBH.
----------------
Backed by Perceptive Advisors

Kiwi

Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Business Wire · Apr-08-2026 9:00 AM ET
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (AMLX.NaE) (“Amylyx” or the “Company”) today announced that management will present at the 25th Annual Needham Virtual Healthcare Conference. The corporate presentation will take place on Wednesday, April 15, 2026, at 8:45 a.m. ET.

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website, https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the event.
------------------------

Kiwi

Last participant has been randomized and dosed in the LUCIDITY trial of avexitide; LUCIDITY enrolled a total of 78 participants
Topline data readout on track; anticipated in Q3 2026
LUCIDITY is evaluating the FDA-agreed-upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16


Kiwi

Amylyx Shares Slip Despite Q4 Beat as Investors Focus on Trial TimelineMarch 3, 2026 10:54 AM
IH Market News
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) posted better-than-expected fourth-quarter results on Tuesday, but shares declined more than 3% in premarket trading as investors assessed the company’s regulatory and commercialization outlook.The biotech reported a quarterly loss of $0.30 per share, narrower than the analyst consensus estimate of a $0.34 loss. Revenue was not disclosed for the quarter. For full-year 2025, Amylyx posted a net loss of $1.53 per share, improving significantly from a loss of $4.43 per share in 2024.The company also announced that patient recruitment has been completed for its pivotal Phase 3 LUCIDITY trial evaluating avexitide in post-bariatric hypoglycemia (PBH). Management said the final eligible participants are expected to be randomized and dosed this month, with topline data projected for the third quarter of 2026. If the therapy gains approval, Amylyx is targeting a commercial launch in 2027.“2025 was a year of meaningful advancement for Amylyx’s pivotal avexitide program in post-bariatric hypoglycemia, as well as progress across our broader pipeline,” said Co-CEOs Joshua Cohen and Justin Klee. “With recruitment of LUCIDITY complete, we are on track to complete enrollment this month and continue to expect topline data in Q3 2026.”Operating expenses declined year over year. Research and development costs fell to $21.2 million in the fourth quarter from $22.9 million a year earlier, reflecting lower spending on AMX0035 development for ALS and PSP, partially offset by increased investment in avexitide trials. Selling, general and administrative expenses decreased to $15.4 million from $17.1 million in the prior-year period.As of December 31, 2025, Amylyx held $317.0 million in cash, cash equivalents and short-term investments, down from $344.0 million at the end of the third quarter. The company said its current cash position is expected to fund operations into 2028, including preparations for a potential avexitide launch.Amylyx Pharmaceuticals stock price

Original: Amylyx Shares Slip Despite Q4 Beat as Investors Focus on Trial Timeline

I guess I missed this post. Unfortunately I am not in AMLX as low as you and Ernie. Still, if we see over $20 I will be not be sad.

I agree, the market seems a lil bit toppy to me which makes DD that much more important.

OT - I'm 100% back thanks to an amazing hospital system - and I'm now looking for upcoming heart related stocks with a future.

No worries RMB I'm back home at probably better than 100% and the icing on the cake is my HSCSW are up 494% today. Sort of ironic in my opinion.

AMLX is a long term hold for me as I've already banked good money on the small amount I sold a while back.

Ernie, sorry I am so late with well wishes.  First time looking through you posts I only saw a HA in 2016, but now rereading I see that you just had one. Glad that you have bounced back and doing well.  One day, when we have made our fortunes with some of these stocks I will tell you a funny story about Sarasota.  Take care. 

Noooo mine is Colombian and wouldn't trade her for the world

Thanks I feel fantastic, amazing group of doctors only drawback will be having to visit VA cardio docs for follow up - I sure as hell can't afford sarasota prices.

I'm assuming thats your wife in the photo ...so yes you need to stick around :--)
Kiwi

Good luck buddy hope you feel better soon 😀🙏

Good info. Yes last lisonpril was monday morning and started Brillenta yesterday PM along with Entresto also started and stopped metporolol to add entresto.

I was really impressed with this visit, I got out about an hour ago, my first HA in 2016 was what they called "massive" requiring the triple bypass and week stay and 2 weeks home visits.

Yes, if I have the gene I will definitely consult with cardiac team as they are the investigators here in Sarasota.

The hospital is sending me a scale, BP cuff, Oxygen sensor and tablet so I can send my daily stats for them to monitor then I send back after 30 days of monitoring.

I feel really good and just need to get used to the new meds and get the wife to calm down.

OT: Ernie, I'm sorry that happened to you-- glad you pulled through and are still with us and able to think and post about investing!

Kiwi, You are a prince, sharing your knowledge and helping Ernie with this advice.

I'm no doctor and don't have anything to add about your meds or the trial, but just want to wish you both well.

On the markets side, I'm starting to feel like everyone is getting too optimistic, and things are bouncing back from bad news too fast. It's when people least expect it that something comes out of nowhere (bad event in Taiwan?) and the VIX spikes and things tank. It may be early to anticipate that, but I just have a feeling something crazy is bound to happen in the "not too distant future," as they say.

Your thoughts?

All best--
-Kaivamei

Hi Ernie ...some quick notes
If you are now on Brilinta ask them if you should stop using the baby aspirin . Being on both may increase the risk of bleeding .
Lysinopril is usually stopped before going on Entresto ( from memory ). Entresto is better .
Jardiance is a great drug .
I think you said you were diabetic and had had bypass surgery .
If so they are trying to carefully craft the optimal med package for you .

I'd wait a week if they said you had the gene they were testing in the trial you mentioned .
I'd want to know if taking the trial drug interfered with your new drug regime and what were the known side effects . They should know that from the first trial
There are benefits being in a clinical trial ...but also risks

Hope this helps .
Above is JMO ...I'm not an MD
Good luck
Kiwi

I quit smoking in 2011. I've been tweaking my diet and now there will be more changes coming.

It will be about a week to see if I have the gene they are wanting, low change since 40% are black and 30% hispanic/asian so will see what happens.

This does give me another area I have never really looked into for possible stocks so I will be spending some time researching those now.

Thanks Kiwi, the trial you referenced I believe was the previous one that was in process when COVID it so they think the results were compromised due to possible COVID patients in the study. The one they have presented to me is dal-GenE-2, got blood draw yesterday to see if I have the AA genomes they are studying as most favorable from the limited reading I've done thus far.

As for my med list, that is changing rapidly so when they get them all on board I will send to you. I've been on Lysinopril since 2016 (triple bypass), metoperol, atorvastin, baby aspirin and then Jardiance and metformin for diabetes but like I said meds are changing, lysinopril is STOPPED. Brillenta and Enturo are new and I'm sure there will be a few more. Please understand my spelling in not from labels but just my phonetics.

Strangest thing is I just had my semi annual appointment a week ago this past monday and Monday afternoon it hit me hard.

RMB. are you in AMLX ...chk Ernie's recent post

Kiwi

Ernie ...you need to have the ADCY AA gene ...20 % of the Nth American population have it .
Their drug appears to work like a PCSK9 ...( Repatha )
They are only looking for a 20% reduction in risk of a heart attack .
If you are on full medical protocol .. whatever they prescribe ...stick to it , dont smoke , eat a mediterean type diet and exercise ...plus an annual flu shot ...you've probably cut your risk in half . Not sure adding their drug would make a lot of difference .. It didn't in the first trial they ran .

The hospital you're in is the only hospital in the US running this trial ....I couldn't find listings of others .
If the Cardiology community was really behind this you'd see UCLA, Harvard , Stanford etc recruiting also .

You have 11 wks after release from the hospital to enroll ...so time to think about it .
I have been in clinical trials for heart disease drugs .
It was the only way I could get some health care coverage before ObamaCare ...I was a Lab rat :--)
Good thing about them is you get a lot of medical attention which helps you stay healthy

Good luck ...and on release ...do what your Cardiologist tells you to do .

Kiwi

Wow Ernie ...a heart attack ??
First off ...follow closely what your Cardiologist advises . Were you on a statin previously ...if you are on one now stay on it . You are probably on blood thinners ... if you're into it send me a list of the drugs you're on and what they want you to do .
If you smoke ....consider the cig you had before this event to be your last .
They will put you on an exercise schedule at some pt ...stick to it.

Males on my father's side die early from heart attacks unless on meds. It's an inherited condition where our livers dont clear cholesterol properly .
I'm on max med therapy ...Repatha , Crestor and Vascepa ...plus dont smoke , med diet and exercise . There is thousands of pages of clinical research showing doing this reduces your risk of a first heart attack or following heart attacks

I'll look into the drug you mentioned ...is this it ?
Kiwi
Dalcetrapib (JTT-705) is a drug that inhibits Cholesteryl Ester Transfer Protein (CETP) to raise HDL ("good") cholesterol, but large trials (like dal-OUTCOMES) showed it didn't reduce cardiovascular events in most patients, despite effectively increasing HDL

Its driving LDL cholesterol as low as possible that reduces CV events .
My baseline was 312 mg/dl
Its now under 50 mg/dl
Whats your LDL cholesterol level ?

Drugs that raise HDL haven't reduced CV ( cardiovascular events ) significantly ...so far

I need a favor from you bio guys, I'm seeing if I qualify for a clinical trial, Dal-GenE-2 study to evaluate the effect of dalbetrapib (study drug) on risk of having a major cardiovascular event, including death, heart attack and stroke.

This is thru DalCor Pharnaceuticals in Canada.

Monday evening I got my azz smacked down with a heart attack, they put a large stent in tuesday and I'm back in action, hopefully tomorrow, at least release from hospital.

I ask because my local hospital is one of the investigational sites with top tier cardiologists I mean top tier. And I can't DD trials like you guys can.

Thanks

Thx Ernie ...good day today
Kiwi

3. Amylyx Pharmaceuticals Inc. (NASDAQ:
AMLX
$14.30 +5.77%
Number of Hedge Fund Holders: 37

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is one of the overlooked growth stocks to buy. On January 8, Amylyx Pharmaceuticals (NASDAQ: AMLX) announced the nomination of AMX0318 as its newest development candidate. Identified through a strategic collaboration with Gubra A/S, AMX0318 is a novel, long-acting glucagon-like peptide-1/GLP-1 receptor antagonist designed to treat post-bariatric hypoglycemia/PBH and other rare diseases.

The development of AMX0318 utilized Gubra’s proprietary streaMLine platform, which is an AI-driven technology used to optimize peptide candidates. Amylyx plans to initiate IND-enabling studies for AMX0318 later in 2026, with a target of filing an IND application in 2027. This new program complements Amylyx’s existing lead candidate, avexitide, which is currently being evaluated in the pivotal Phase 3 LUCIDITY trial for PBH. The company expects to finish recruitment for the LUCIDITY trial in Q1 2026 and anticipates a topline data readout in Q3 2026.

Earlier on December 19, Bank of America lowered the firm’s price target on Amylyx to $15 from $16, while keeping a Buy rating on the shares. Following Amylyx’s Q3 2025 earnings report, the firm highlighted that recent financing secured the company’s cash runway through 2028. BofA noted that the stock’s primary catalyst remains the Phase 3 LUCIDITY trial for avexitide. Data from this pivotal study, which targets post-bariatric hypoglycemia, is expected in Q3 2026.

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) is a clinical-stage pharmaceutical company that discovers and develops treatment options for neurodegenerative diseases and endocrine conditions in the US.

RLMD has been good to me and look for better days on it also. Unfortunately I'm only up 1080% right now but it will get better I'm sure.

Still here and RZLT and a few others

Still in AMLX Ernie ? Well done ( so far ) on RZLT

Kiwi

Still in AMLX Ernie ? Well done ( so far ) on RZLT

Kiwi

I saw that also earlier today, I'm still in just wish I had added harder on RZLT when I bought at $1.20ish during the carnage. It is showing amazing strength and would happily add more if it drops back down under $2 but I think those chasing are dwindling.

Now I'm hunting for some dementia related tickers to add to my stable.

The AMLX and RZLT overlap... Gemini's AI

Would RZ358 ( RZLT ) also work with these patients
Yes, RZ358 (ersodetug) has shown potential for treating patients with post-bariatric hypoglycemia (PBH), also referred to as post-gastric bypass hypoglycemia (PGBH).
While avexitide (Amylyx) targets the excessive GLP-1 that triggers insulin spikes, RZ358 works downstream by blunting the insulin receptor itself. This makes it a potential treatment for PBH even though it does not directly address the GLP-1 hormone.
RZ358 Performance in PBH Trials
Rezolute has presented positive data from Phase 2a clinical studies specifically in the PBH population:
Clinically Significant Improvement: Treatment with RZ358 resulted in an improvement in hypoglycemia of more than 50%, leading to near-normalization of average glucose levels.
Sustained Target Range: Patients experienced at least a 50% increase in time-in-target blood glucose range (70–180 mg/dL).
Self-Regulating Mechanism: Because RZ358 is an allosteric modulator, its effect is "disease-severity dependent"—it increases plasma glucose only when insulin is elevated, which prevents the risk of causing high blood sugar (hyperglycemia).
Safety Profile: The drug was reported as safe and well-tolerated in these patients, with no serious adverse reactions or study discontinuations.
Strategic Status
Despite these positive Phase 2 results, Rezolute’s primary development focus for RZ358 in 2025 has been on congenital hyperinsulinism (cHI) and tumor-mediated hyperinsulinism. Amylyx’s avexitide is currently further ahead in the specific PBH indication, having advanced into a pivotal Phase 3 trial (LUCIDITY) as of 2025.

Karen Firestone just made an Open Market purchase
Karen Firestone is a regular contributor on CNBC and appears frequently on the network's programs. She is also a Director on the board of Amylyx Pharmaceuticals (AMLX).
CNBC Contributor: Ms. Firestone appears on shows such as the Half Time Report, Squawk Box, and Worldwide Exchange. She also writes for the CNBC.com website.
Amylyx Director: She has served as an independent director on the Amylyx Pharmaceuticals board since March 2023.
In addition to these roles, she is the Co-founder and Chair Emerita of Aureus Asset Management.


Kiwi

Amylyx Q3 2025 update:
* Avexitide (PBH):
* Phase III LUCIDITY enrollment extends to Q1 2026; topline Q3 2026. Launch still targeted for 2027.
* High participant interest.
* Market research supports 160K U.S. PBH population.
----------------
Kiwi

Well stock may be trailing off due to this recent statement by Ceo
Our previous estimates assumed a ramp in the enrollment rate at this stage of the trial, but we have seen more of a steady enrollment rate in the last few weeks.
So maybe longer to trial completion and data then what they previously projected
Kiwi

Is he standing on his head? It's moving the opposite of where it should have been going.

I'm sooooo confused

HC Wainwright & Co. analyst Andrew Fein maintains Amylyx Pharmaceuticals (AMLX.NaE) with a Buy and raises the price target from $16 to $20....today

Kiwi

Unwarranted smackdown on fins - they are in a very good position running into 2026

I'm ready to see it over $20